Our Recommendations
New Publications
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
- Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance (2022)
- Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S [recombinant] vaccine (Convidecia™) against COVID-19: interim guidance, first issued 19 May 2022 (2022)
Filter
132
Featured
Recommendations
24
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
Countries
55
Key Resources
2
Women & Child Health
1
La stratégie continentale commune africaine pour COVID-19 est sous-tendue par la nécessité de limiter la transmission, de prévenir les décès et de réduire les dommages associés. La participation des nations africaines aux essais cliniques est une étape essentielle pour garantir la productio...
10 December 2020
Stand 1.12.2020
PhD Martin Moder, österreichischer Molekularbiologe, Autor populärwissenschaftlicher Bücher und Teil der Wissenschaftskabarettgruppe Science Busters, erklärt die Wirkweise und potentiellen Risiken der mRNA-Impfstoffe gegen COVID19
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This...
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...
Evaluation of the effectiveness of vaccines against COVID-19
INTERIM GUIDANCE 17 MARCH 2021
Vaccine handling, storage and Transportation of Pfizer BioNTech
COVID-19 COMIRNATY® (Tozinameran)
